Abstract
Little is known on strategies to prevent or to treat relapses occurring after haploidentical stem cell transplantation (haplo-HSCT) performed for the high-risk neuroblastoma (NB). We describe a 6-year-old male with refractory NB who relapsed 22 months after haplo-HSCT. A complete remission was obtained with a combination of immuno-chemotherapy based on donor NK cells transplants, IL2 infusions and temozolomide/topotecan. This case is an incentive to explore both the immediate therapeutic effect of haplo-graft provided via haplo-NK cells and the immunogenic platform that haplo-HSCT offers for future treatment. Our post-relapse strategy shows that chemo- and bio-treatment should be viewed as complementary therapeutic options.
Copyright © 2011 Wiley Periodicals, Inc.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adrenal Gland Neoplasms / pathology
-
Adrenal Gland Neoplasms / therapy*
-
Antineoplastic Agents, Alkylating / therapeutic use
-
Biomarkers, Tumor / analysis
-
Bone Marrow Neoplasms / secondary
-
Bone Neoplasms / secondary
-
Child
-
Combined Modality Therapy
-
Dacarbazine / analogs & derivatives
-
Dacarbazine / therapeutic use
-
Doublecortin Domain Proteins
-
Haplotypes
-
Hematopoietic Stem Cell Transplantation*
-
Homeodomain Proteins / analysis
-
Humans
-
Immunotherapy*
-
Interleukin-2 / therapeutic use
-
Killer Cells, Natural / transplantation*
-
Male
-
Microtubule-Associated Proteins
-
Neoplasm, Residual
-
Neuroblastoma / pathology
-
Neuroblastoma / secondary
-
Neuroblastoma / therapy*
-
Neuropeptides
-
Remission Induction
-
Temozolomide
-
Topotecan / therapeutic use
-
Transcription Factors / analysis
-
Transplantation, Homologous
-
Tyrosine 3-Monooxygenase / analysis
Substances
-
Antineoplastic Agents, Alkylating
-
Biomarkers, Tumor
-
Doublecortin Domain Proteins
-
Homeodomain Proteins
-
Interleukin-2
-
Microtubule-Associated Proteins
-
NBPhox protein
-
Neuropeptides
-
Transcription Factors
-
Dacarbazine
-
Topotecan
-
Tyrosine 3-Monooxygenase
-
Temozolomide